Hypertriglyceridemia: Difference between revisions
imported>Robert Badgett No edit summary |
imported>Robert Badgett |
||
| Line 8: | Line 8: | ||
"Patients in whom triglycerides >500 mg/dL should receive strict diet therapy including avoidance of alcohol, restriction of dietary fat, and avoidance of concentrated carbohydrates (sweets). For triglycerides >1000 mg/dL a very low fat diet should be instituted quickly to reduce chylomicronemia and risk of acute pancreatitis" | "Patients in whom triglycerides >500 mg/dL should receive strict diet therapy including avoidance of alcohol, restriction of dietary fat, and avoidance of concentrated carbohydrates (sweets). For triglycerides >1000 mg/dL a very low fat diet should be instituted quickly to reduce chylomicronemia and risk of acute pancreatitis" | ||
Regarding treating triglycerides among patients with [[diabetes mellitus]] with levels less than 650 mg/dl, "the combination of fenofibrate and simvastatin did not reduce the rate of fatal cardiovascular events, nonfatal myocardial infarction, or nonfatal stroke, as compared with simvastatin alone" according to a [[randomized controlled trial]]. <ref name="pmid20228404">{{cite journal| author=ACCORD Study Group. Ginsberg HN, Elam MB, Lovato LC, Crouse JR, Leiter LA et al.| title=Effects of combination lipid therapy in type 2 diabetes mellitus. | journal=N Engl J Med | year= 2010 | volume= 362 | issue= 17 | pages= 1563-74 | pmid=20228404 | url=http://www.nejm.org/doi/full/10.1056/NEJMoa1001282}}</ref> However, among the diabetics with triglycerdies about 204 and HDL less than 34, there was significant better (primary outcome over 5 years reduced from 17% to 12%).<ref name="pmid20228404"/> | Regarding treatment, the AIM-HIGH found that niacin did not reduce the risk of cardiovascular events.<ref>{{cite web |url= http://public.nhlbi.nih.gov/newsroom/home/GetPressRelease.aspx?id=2792 |title=NHLBI - Press Release |author=Anonymous |work=public.nhlbi.nih.gov |year=2011 [last update] |accessdate=July 26, 2011}}</ref> | ||
Regarding treating triglycerides among patients exclusively with [[diabetes mellitus]] with levels less than 650 mg/dl, "the combination of fenofibrate and simvastatin did not reduce the rate of fatal cardiovascular events, nonfatal myocardial infarction, or nonfatal stroke, as compared with simvastatin alone" according to a [[randomized controlled trial]]. <ref name="pmid20228404">{{cite journal| author=ACCORD Study Group. Ginsberg HN, Elam MB, Lovato LC, Crouse JR, Leiter LA et al.| title=Effects of combination lipid therapy in type 2 diabetes mellitus. | journal=N Engl J Med | year= 2010 | volume= 362 | issue= 17 | pages= 1563-74 | pmid=20228404 | url=http://www.nejm.org/doi/full/10.1056/NEJMoa1001282}}</ref> However, among the diabetics with triglycerdies about 204 and HDL less than 34, there was significant better (primary outcome over 5 years reduced from 17% to 12%).<ref name="pmid20228404"/> | |||
==References== | ==References== | ||
<references/> | <references/> | ||
Revision as of 23:27, 25 July 2011
In medicine hypertriglyceridemia is a dyslipidemia and is "a condition of elevated levels of triglycerides in the blood".[1]
One cause is hypoalphalipoproteinemia.
Treatment
Clinical practice guidelines state:[2] "Patients in whom triglycerides >500 mg/dL should receive strict diet therapy including avoidance of alcohol, restriction of dietary fat, and avoidance of concentrated carbohydrates (sweets). For triglycerides >1000 mg/dL a very low fat diet should be instituted quickly to reduce chylomicronemia and risk of acute pancreatitis"
Regarding treatment, the AIM-HIGH found that niacin did not reduce the risk of cardiovascular events.[3]
Regarding treating triglycerides among patients exclusively with diabetes mellitus with levels less than 650 mg/dl, "the combination of fenofibrate and simvastatin did not reduce the rate of fatal cardiovascular events, nonfatal myocardial infarction, or nonfatal stroke, as compared with simvastatin alone" according to a randomized controlled trial. [4] However, among the diabetics with triglycerdies about 204 and HDL less than 34, there was significant better (primary outcome over 5 years reduced from 17% to 12%).[4]
References
- ↑ Anonymous (2024), Hypertriglyceridemia (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ [Management of Dyslipidemia Working Group. VA/DoD clinical practice guideline for the management of dyslipidemia. Washington (DC): Department of Veterans Affairs, Department of Defense; 2006. 140 p.
- ↑ Anonymous (2011 [last update]). NHLBI - Press Release. public.nhlbi.nih.gov. Retrieved on July 26, 2011.
- ↑ 4.0 4.1 ACCORD Study Group. Ginsberg HN, Elam MB, Lovato LC, Crouse JR, Leiter LA et al. (2010). "Effects of combination lipid therapy in type 2 diabetes mellitus.". N Engl J Med 362 (17): 1563-74. PMID 20228404.